---

---

crawled date : 2022 - 11 - 03    source : Www.biospace.com   

save search

---

Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
Published: 2022-11-03 (Crawled : 23:00) - biospace.com/
PRTA 4 | $20.6 -1.91% -1.94% 570K |

Health Technology

| -64.91% | O: -1.99% H: 0.55% C: -1.64%
financial results

---

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
Published: 2022-11-03 (Crawled : 23:00) - biospace.com/
VSTM | $10.19 -6.0% -6.38% 67K |

Health Technology

| 130.97% | O: -0.28% H: 7.69% C: 2.23%
GERN | $3.72 1.09% 1.08% 9.7M |

Health Technology

| 71.16% | O: 0.93% H: 4.15% C: -6.45%
financial results ras pathway

---

Puma Biotechnology Reports Third Quarter 2022 Financial Results
Published: 2022-11-03 (Crawled : 23:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| 0.15% | O: -0.91% H: 0.92% C: 0.77%
PBYI | $4.98 -3.68% -3.82% 290K |

Health Technology

| 139.35% | O: 0.0% H: 1.85% C: -0.93%
financial results

---

Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates
Published: 2022-11-03 (Crawled : 23:00) - biospace.com/
CRDF | $4.355 -3.22% -3.33% 830K |

Health Services

| 208.05% | O: 0.0% H: 1.01% C: -4.7%
results

---

Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study
Published: 2022-11-03 (Crawled : 20:00) - biospace.com/
SHPH | $0.4099 -2.69% 11K |

| -82.17% | O: 0.87% H: 2.16% C: -4.31%
pharmaceuticals study

---

Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1
Published: 2022-11-03 (Crawled : 19:00) - biospace.com/
GRFS | News | $6.53 -0.76% -0.77% 760K |

Health Technology

| 1.39% | O: -0.46% H: 0.0% C: -1.24%
fda clearance risk free service

---

Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition
Published: 2022-11-03 (Crawled : 19:00) - biospace.com/
PSTX | News | $2.005 -1.72% -1.75% 520K |

Health Technology

| -46.6% | O: -0.52% H: 7.63% C: 6.84%
fviii-101 meeting therapeutics presentation therapy

---

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting
Published: 2022-11-03 (Crawled : 19:00) - biospace.com/
NBIX M | $132.49 -0.56% -0.56% 550K |

Health Technology

| 9.15% | O: -0.09% H: 2.71% C: 1.77%
ingrezza meeting in vitro

---

CTI BioPharma Announces Oral Presentation at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition
Published: 2022-11-03 (Crawled : 19:00) - biospace.com/
CTIC | $9.09 0.05% 11M |

Health Technology

| 85.61% | O: 2.24% H: 3.29% C: 0.2%
biopharma meeting presentation

---

Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias
Published: 2022-11-03 (Crawled : 19:00) - biospace.com/
SNDX | $20.44 -1.45% -1.47% 1.2M |

Health Technology

| -9.39% | O: -0.57% H: 13.62% C: -1.89%
gment-101 trial positive phase 1

---

GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting
Published: 2022-11-03 (Crawled : 15:20) - biospace.com/
GLYC | $2.16 -5.26% -5.56% 880K |

Health Technology

| 222.22% | O: -1.43% H: 2.39% C: -0.76%
meeting leukemia acute myeloid leukemia

---

Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
Published: 2022-11-03 (Crawled : 15:00) - biospace.com/
GRCL | $10.25 -0.29% 6.4M |

Manufacturing

| 211.09% | O: -1.52% H: 25.31% C: 12.35%
gc012 meeting

---

Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition
Published: 2022-11-03 (Crawled : 15:00) - biospace.com/
RIGL | $1.06 -4.51% -4.72% 1.2M |

Health Technology

| 57.94% | O: -0.26% H: 5.56% C: 3.5%
meeting

---

Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
Published: 2022-11-03 (Crawled : 15:00) - biospace.com/
SYRS | $4.76 -6.85% -7.35% 120K |

Health Technology

| 20.24% | O: -0.47% H: 3.07% C: -0.71%
pharmaceuticals meeting trial phase 2 aml

---

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
Published: 2022-11-03 (Crawled : 15:00) - biospace.com/
KZR | $0.7896 -3.31% -3.42% 540K |

Health Technology

| -88.86% | O: -1.63% H: 3.45% C: -1.52%
sciences meeting lupus life kidney week trial positive results

---

Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial
Published: 2022-11-03 (Crawled : 14:20) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K |

Health Technology

| -46.29% | O: 0.42% H: 4.49% C: -11.82%
aml trial positive phase 1

---

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
GNMSF | $281.02 3.83% 210 |

Health Technology

| -26.99% | O: -2.44% H: 5.65% C: 5.65%
ADCT | $4.76 -4.03% 0.0% 280K |

Health Technology

| 7.51% | O: -2.18% H: 8.91% C: 8.17%
GMAB | $28.32 -0.74% -0.74% 240K |

Health Technology

| -26.51% | O: -1.73% H: 4.51% C: 3.15%
meeting therapeutics presentation

---

Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
XNCR | $18.98 -0.47% -0.47% 470K |

Health Technology

| -30.48% | O: -0.84% H: 1.99% C: -0.4%
meeting study phase 1

---

Vaxcyte to Present at Upcoming Investor Conferences
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
PCVX | $60.65 -2.85% -2.93% 660K |

Health Technology

| 46.83% | O: -0.07% H: 6.9% C: 5.48%
STRO M | $3.76 -1.05% -1.06% 770K |

Health Technology

| -48.09% | O: -1.23% H: 7.61% C: 1.94%

---

Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
ALPN | $64.45 -0.02% -0.02% 2.5M |

Health Technology

| 974.17% | O: -0.17% H: 9.68% C: 7.68%
alpn-303 sciences meeting study phase 1

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---